Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 12/20 | 0.60 |
| ▸ | OGFRL1 | Q5TC84 | 8/20 | 0.60 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL998772 | 0.86 | OPRM1 (0.53) | OPRM1OGFRL1OPRL1LMNAOPRD1 | |
| SCHEMBL12592476 | 0.81 | LMNA (0.60) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL14471060 | 0.79 | LMNA (0.57) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL9480993 | 0.77 | LMNA (0.52) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL10038853 | 0.75 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1LMNAOPRD1 | |
| SCHEMBL517133 | 0.75 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1LMNAOPRD1 | |
| Hydrochloric Acid SCHEMBL8820315 | 0.74 | LMNA (0.46) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| Hydrochloric Acid SCHEMBL1303569 | 0.74 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1LMNAOPRD1 | |
| SCHEMBL17807190 | 0.74 | OPRM1 (0.69) | OPRM1OGFRL1OPRL1LMNAOPRD1 | |
| SCHEMBL10051500 | 0.73 | LMNA (0.69) | OPRM1OGFRL1OPRL1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3109385-A | — | — | None | — | — | JP | disclosed |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | PTC THERAPEUTICS, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| US-8133992-B2 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| EP-1532153-B1 | AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | X CEPTOR THERAPEUTICS INC (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20090326218-A1 | Azepinoindole and Pyridoindole Derivatives as Pharmaceutical Agents | EXELIXIS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-7485634-B2 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| EP-1532153-A1 | AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | X-Ceptor Therapeutics, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040023947-A1 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | X-CEPTOR THERAPEUTICS INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003099821-A1 | AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| JP-H03109385-A | NEW TRICYCLIC AMINE COMPOUND AND SALT THEREOF | FUJISAWA PHARMACEUT CO LTD | 1991-05-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023947-A1 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | HTR5A, MTNR1A, PTGDR | OPRM1 140/4885OGFRL1 773/4885OPRL1 115/4885 |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | SARS1, EIF2AK2, POLRMT | OPRM1 3341/4885OGFRL1 1883/4885OPRL1 3627/4885 |
| US-20090326218-A1 | Azepinoindole and Pyridoindole Derivatives as Pharmaceutical Agents | HTR5A, MTNR1A, PTGDR | OPRM1 140/4885OGFRL1 773/4885OPRL1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.